Clinical and economic efficacy of ribosomal therapy in children in the prevention of acute respiratory infections

The article tells about the problem of acute respiratory infections in preschool children. Pharmacoeconomic efficacy of ribosomal immunomodulatory therapy for the prevention of acute respiratory infections is evaluated. The study found that ribosomal therapy with Ribomunyl has financial benefits and allows to dwindle almost by half the cost of treatment of acute respiratory infections within 2 years after treatment